REsponse Adapted Combination Therapy by BIOTRONIK: 
REACT to the Vessel Response with clinically proven treatment options.

In SFA interventions there is no ‘one solution fits all’. 
The treatment approach is often determined following PTA lesion preparation.

Stenting can cause vessel injury and inflammation. Many physicians prefer limiting the amount of implanted metal as their initial endovascular strategy.

With REACT you can implant a stent only when and where needed, while benefiting from Paclitaxel effect across full lesion length.

This versatility is not possible with drug eluting stents.

REACT Options are only clinically proven when used with BIOTRONIK's 
Passeo-18 Lux DCB and Pulsar Stent (individually or in combination).

1 Rocha-Singh K, Tepe G, Schneider P, Zeller T. Refi ning Strategies for the SFA: Consensus Panel SFA Treatment Algorithm, Supplement to Endovascular Today Global, Spring 2014: 11; 2 Keirse K. Leaving The Right Thing Behind: BIOLUX P-III Global All-Comers Registry 12 month interim results. Presented at LINC 2017; 3 Deloose K. DCB + Stent in the SFA: Full 12-month data of the BIOLUX 4EVER trial (365 days). Presented at Charing Cross 2017; 4 Lichtenberg M.
BIOFLEX PEACE Registry 12-month analysis (395 days). Presented at Charing Cross 2017; 5 DEBAS. Mwipatayi P. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease. Sage Journals. 2017; 0(0) 1–9, 24-month data; 6 The use of Passeo-18 Lux for post-dilatation is not within the indication for the product. PTA = Percutaneous Transluminal Angioplasty; PP = Primary Patency; DCB = Drug-Coated Balloon; fTLR = freedom from Target Lesion Revascularization for BIOFLEX PEACE and BIOLUX 4EVER and freedom from clinically driven TLR for BIOLUX P-III and DEBAS; SFA = Superficial Femoral Artery